Value-based pricing: UK drug industry shifts influence away from HTA body
This article was originally published in SRA
Executive Summary
The UK pharma industry association, the ABPI, has won a victory over NICE, the health technology appraisal institute for England and Wales, in the ongoing negotiations over value-based pricing. Currently, NICE sets the cost-effectiveness thresholds that influence UK drug pricing and the role of NICE itself was outside the ABPI’s sphere of influence. However, the ABPI's chief executive Stephen Whitehead told Scrip Regulatory Affairs sister publication Scrip Intelligence, that those thresholds are now part of the negotiations rather than being outside them.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.